PT  - JOURNAL ARTICLE
AU  - Nichols, Emma Hitt
ED  - Greenberg, Barry H.
TI  - Emerging Pharmacotherapies: The Future of Heart Failure Management
DP  - 2013 May 01
TA  - MD Conference Express
PG  - 34--36
VI  - 13
IP  - 2
4099  - http://mdc.sagepub.com/content/13/2/34.short
4100  - http://mdc.sagepub.com/content/13/2/34.full
AB  - Patients with heart failure (HF) often remain symptomatic and have a poor prognosis despite treatment with existing therapies [Cleland JG et al. Lancet 2011]. Several new therapeutic options are currently emerging for HF, including direct renin inhibitors, neprilysin inhibitors, selective If channel inhibitors, cardiac myosin activators, vasopressin receptor antagonists, and phosphodiesterase type 5 inhibitors. This article discusses clinical trial data for direct renin inhibitors and neprilysin inhibitors.